lu 135252 has been researched along with Hypercholesterolemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hergenröder, S; Kirchengast, M; Münter, K | 1 |
| Brehme, U; Claussen, CD; Duda, SH; Raschack, M; Seeger, H; Tepe, G | 1 |
2 other study(ies) available for lu 135252 and Hypercholesterolemia
| Article | Year |
|---|---|
Endothelin-A receptor antagonist combined with hydralazine improves survival and renal function in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Endothelin Receptor Antagonists; Hydralazine; Hypercholesterolemia; Hypertension; Kidney; Kidney Function Tests; Male; Phenylpropionates; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Receptor, Endothelin A; Survival | 1998 |
Endothelin A receptor antagonist LU 135252 inhibits hypercholesterolemia-induced, but not deendothelialization-induced, atherosclerosis in rabbit arteries.
Topics: Animals; Arteriosclerosis; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Hypercholesterolemia; Immunohistochemistry; Phenylpropionates; Pyrimidines; Rabbits; Receptor, Endothelin A | 2002 |